SmallCapReview - Small Cap Stocks to Watch - CYCC, TASR, MRGE

Cyclacel Pharmaceuticals ( Nasdaq : CYCC) $2.40. Today announced that a newly published study demonstrates that the company's seliciclib, an orally available inhibitor of multiple cyclin-dependent kinases, reversed resistance to the aromatase inhibitor letrozole (Femara) and killed hormone receptor positive breast cancer cells that had become insensitive to the effects of letrozole. The new study was published in the current edition of Clinical Cancer Research, a journal of the American Association for Cancer Research. Seliciclib is currently in Phase 2 clinical trials for non-small cell lung cancer and nasopharyngeal cancer.

"Resistance to aromatase inhibitors, such as letrozole, is a major challenge for the long-term management of hormone receptor positive breast cancer," said Professor David Glover, Ph.D., Cyclacel's Chief Scientist. "The data published in Clinical Cancer Research are encouraging as they show that seliciclib can kill resistant breast cancer cells by targeting a form of cyclin E that is a major cause of the resistance. This is further evidence that seliciclib's unique mechanism of action can be effective against certain cancer cells, such as breast and lung cancer, that fail to respond to standard cancer treatments."

Approximately 3 out of 4 women suffering from breast cancer after menopause have cancers that express the hormonal receptors for estrogen and progesterone and are offered treatment with aromatase inhibitor drugs including letrozole. Letrozole treatment reduces the risk of early metastasis in women with estrogen receptor positive breast cancer. Letrozole is believed to interact with a natural CDK inhibitor p27 which in turns regulates the activity of the CDK2/cyclin E complex. Over time, breast cancer cells develop resistance to letrozole and the therapy becomes ineffective.  

TASER International ( Nasdaq : TASR) $5.95. Today announced that it received an order for 150 TASER X3 Electronic Control Devices and related accessories for the Lakeland Police Department, FL.  The TASER X3 is the latest, most sophisticated ECD model from TASER with a three-shot semi-automatic capability.

The TASER X3 enhances use of force accountability with the TASER X3's Trilogy Log, which stores the electric characteristics of every pulse emitted from the X3 and can determine if the charge was delivered to a subject, arced into the air as a warning, if probes missed the target, or even if the wires broke or some other factor interrupted charge delivery to the subject.

Merge Healthcare ( Nasdaq : MRGE) $2.35. Today announced that it has signed a reseller agreement with Orion Health, a leading provider of clinical workflow and integration solutions in healthcare. Orion Health has licensed Merge technology to bring medical images and information into its physician portal solutions.

“An integrated medical record helps healthcare organizations improve the quality of care by bringing more complete information into medical decision making at the point of care,” says Paul Viskovich, President of Orion Health, North America and EMEA. “Our customers find that images are a particular challenge, and have been asking us for imaging integration. Merge’s extensive experience in this arena makes them the best partner to help us deliver this to our customers. ” 

What They Do: Merge Healthcare develops solutions that automate healthcare data and diagnostic workflow to enable a better electronic record of the patient experience, and to enhance product development for health IT, device and pharmaceutical companies.

About SmallCapReview

Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com/. To follow us on Twitter visit http://twitter.com/SmallCapReview.